Arcutis Biotherapeutics
ARQT
ARQT
134 hedge funds and large institutions have $357M invested in Arcutis Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 54 increasing their positions, 37 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
48% less capital invested
Capital invested by funds: $684M → $357M (-$327M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
82% less call options, than puts
Call options by funds: $688K | Put options by funds: $3.77M
Holders
134
Holding in Top 10
1
Calls
$688K
Puts
$3.77M
Top Buyers
| 1 | +$1.82M | |
| 2 | +$1.64M | |
| 3 | +$1.57M | |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$1.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.22M |
Top Sellers
| 1 | -$7.62M | |
| 2 | -$5.05M | |
| 3 | -$4.59M | |
| 4 |
Axa
Paris,
France
|
-$4.28M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.21M |